why choose us

300×250 Ad Slot

Research Article: Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer

Date Published: 2025-01-24

Abstract:
Background: Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). However, the efficacy and safety of pralsetinib in real world has rarely been reported.

No summary available.

300×250 Ad Slot